Wave Life Sciences' RNA Editing Therapy Shows Promising Results in AATD Trial
Event summary
- Wave Life Sciences' WVE-006 achieved MZ-like phenotype in RestorAATion-2 trial with biweekly and monthly dosing.
- WVE-006 generated 64% wild-type M-AAT and reduced harmful Z-AAT by 71% in the 200 mg biweekly cohort.
- Editing effects sustained for at least three months post-dosing, with no liver toxicities observed.
- FDA feedback on potential accelerated approval pathway expected mid-2026.
The big picture
Wave Life Sciences' positive RestorAATion-2 trial results position WVE-006 as a potential new standard of care for alpha-1 antitrypsin deficiency (AATD), addressing both lung and liver manifestations. The data reinforce the strategic advantage of RNA editing over DNA editing, offering a reversible, safe, and effective therapy. The upcoming FDA feedback and additional data from the 600 mg cohort will be critical in determining the next steps for WVE-006's development and commercialization.
What we're watching
- Regulatory Pathway
- Whether FDA feedback mid-2026 will support accelerated approval for WVE-006.
- Dosing Flexibility
- The pace at which Wave can establish monthly dosing as the standard for AATD treatment.
- Competitive Positioning
- How Wave's RNA editing approach differentiates from DNA editing and other AATD therapies.
Related topics